A Phase II Study to Evaluate the Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2019
Price : $35 *
At a glance
- Drugs Apixaban (Primary)
- Indications Heparin-induced thrombocytopenia and thrombosis syndrome
- Focus Therapeutic Use
- 01 Dec 2018 Status changed from not yet recruiting to recruiting.
- 14 Sep 2018 Planned initiation date changed from 31 Jul 2018 to 30 Nov 2018.
- 25 Jul 2018 New trial record